- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.05. | Day One Biopharmaceuticals, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
| 23.04. | Servier Acquires Day One Biopharmaceuticals | 9 | Contract Pharma | ||
| 23.04. | Servier completes the acquisition of Day One Biopharmaceuticals | 506 | PR Newswire | Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 23.04. | NSE - Day One Biopharmaceuticals, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 23.04. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.04. | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 13.03. | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | 3.411 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| 11.03. | JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition | 6 | Investing.com | ||
| 10.03. | This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday | 2 | Benzinga.com | ||
| 09.03. | Servier acquires International Biotech's Day One Biopharmaceuticals for USD2.5 billion | 3 | Alliance News | ||
| 09.03. | Intnl. Biotechnology - Portfolio company Day One Biopharmaceuticals acquired by Servier | 1 | RNS | ||
| 07.03. | Key deals this week: Diana Shipping, Day One BioPharmaceuticals, Hudbay Minerals and more | 24 | Seeking Alpha | ||
| 07.03. | Day One Biopharmaceuticals (DAWN) Climbs to 3-Year High on $2.5-Billion Merger | 1 | Insider Monkey | ||
| 06.03. | Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma | 13 | MedCity News | ||
| 06.03. | Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion | 1 | pulse2.com | ||
| 06.03. | Servier Acquires Day One Biopharmaceuticals, Expanding Rare Oncology Portfolio | 2 | Contract Pharma | ||
| 06.03. | Servier to build cancer drug pipeline with $2.5B purchase of Day One Biopharmaceuticals | 1 | BioPharma Dive | ||
| 06.03. | Oppenheimer reiterates Day One Biopharmaceuticals stock rating on Servier deal | 2 | Investing.com | ||
| 06.03. | TD Cowen downgrades Day One Biopharmaceuticals stock on Servier deal | 3 | Investing.com | ||
| 06.03. | Jones Trading cuts Day One Biopharmaceuticals stock rating on Servier acquisition | 1 | Investing.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,35 | +0,25 % | BioNTech Aktie: 1.800 Jobs wackeln und Moderna greift zu | BioNTech steht vor einem tiefen Umbau. Der einstige Hoffnungsträger der deutschen Biotechbranche muss Werke schließen, Stellen streichen und seine Zukunft neu ausrichten. Für Anleger rückt damit die... ► Artikel lesen | |
| AMGEN | 317,50 | -1,40 % | NICE aims to cut funding for Amgen lung cancer drug Lumykras | ||
| NOVAVAX | 8,190 | -0,12 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 172,30 | -1,71 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 03.07.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,795 | -3,94 % | H.C. Wainwright reiterates CRISPR Therapeutics stock rating on label expansion | ||
| VIKING THERAPEUTICS | 35,450 | +1,29 % | Viking Therapeutics: 48 Prozent in einem Monat - Novo-Nordisk-Konkurrent dreht wieder auf | Die Erfolge von Novo Nordisk und Eli Lilly haben dazu geführt, dass viele Biopharma-Unternehmen in die Adipositas-Forschung eingestiegen sind. Viking Therapeutics hingegen widmet sich schon länger metabolischen... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 13,560 | -8,01 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TEMPUS AI | 53,01 | +5,77 % | Freedom Capital Initiates Coverage of Tempus AI, Inc. (TEM) | ||
| BIOCRYST PHARMACEUTICALS | 9,554 | -1,79 % | BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains? | ||
| BIOMARIN PHARMACEUTICAL | 52,02 | -0,42 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen | |
| EXELIXIS | 49,625 | +1,06 % | UBS raises Exelixis stock price target to $52 on pipeline outlook | ||
| SAREPTA THERAPEUTICS | 17,780 | +0,45 % | Wolfe Research upgrades Sarepta Therapeutics stock rating on pipeline outlook | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,416 | +8,22 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,880 | 0,00 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine | No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart... ► Artikel lesen |
DAY ONE BIOPHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 21,530 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.